<?xml version='1.0' encoding='iso-8859-1'?>
<PASBIO>
    <framesest>
        <predicate lemma="develop">
            <roleset id="develop.01" name="" wordnet="10">
                <roles>
                    <role n="0" descr="non-intentional theme&#10;" />
                    <role n="1" descr="thing developed&#10;" />
                    <role n="2" descr="end result&#10;" />
                </roles>
                <example src="EGRAM" no="0">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic female carrier whose son can develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="0">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son can develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son may have developed acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="1">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son may have developed at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>A C-T transition at codon 214, which creates a new RsaI recognition site at exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic woman with whose child develops acute onset of the development of OTC deficiency.</text>
					<arg n="0">whose child</arg>
					<arg n="1">acute onset of the development of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="2">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son develops at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son has the ability to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="3">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son has the ability to develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>A C-T transition at codon 214, which creates a new RsaI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic woman at risk of developing son of acute onset of OTC deficiency at a new RsaI recognition site in exon 6.</text>
					<arg n="0">son</arg>
					<arg n="1">acute onset of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="4">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son risks developing at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is able to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="5">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son is able to develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is thought to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="6">
					<text>A C-T transition to codon 214, which develop a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son is considered to have development at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is developing acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="7">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son is developing at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="8">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son develops at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son develops at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="9">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is observed to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is predicted to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="10">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son is predicted to develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son is shown to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="11">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son has been shown to develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>A C--T transition at codon 214, which creates a new SRSI recognition site at exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose child may develop acute onset of OTC deficit in the neonatal period.</text>
					<arg n="0">whose child</arg>
					<arg n="1">acute onset of OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="12">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son can develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) is identified in an asymptomatic woman carrying whose son may have developed acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="13">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son may have developed at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>A C--T transition at codon 214, which develop a new SRSI recognition site at exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose child will develop acute onset of OTC deficit in the neonatal period.</text>
					<arg n="0">whose child will develop A1 (acute onset of OTC deficit in the neonatal period)</arg>
					<arg n="1">acute onset of OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="14">
					<text>A C-T transition to codon 214, which develop a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son will develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son will develop A1 (at the start of the OTC deficit in the neonatal period)</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>A C--T transition at codon 214, which creates a new SRSI recognition site at exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose child will have developed acute onset of OTC deficit in the neonatal period.</text>
					<arg n="0">whose child</arg>
					<arg n="1">acute onset of OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="15">
					<text>A C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), is identified in an asymptomatic female carrier whose son has developed at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son could develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="16">
					<text>The transition C-T to codon 214, creating a new SSRI recognition site in exon 6 and replacing tyrosine with histidine (H214Y), was identified in an asymptomatic woman carrying whose son could develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son had the ability to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="17">
					<text>The transition C-T to codon 214, creating a new SSRI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y), was identified in an asymptomatic woman carrying whose son had the ability to develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>The C--T transition at codon 214, which creates a new SRSI recognition site at exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose child had the risk of developing acute onset of OTC deficit in the neonatal period.</text>
					<arg n="0">whose child</arg>
					<arg n="1">acute onset of OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="18">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic woman carrying whose son at the risk of developing at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son has been developing high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="19">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son has been developing at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son has developed acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="20">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son developed at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son could develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="21">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son can develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>A C-T transition in codon 214 was identified, which created a new RsaI recognition site in exon 6 and which replaced tyrosine with histidine (H214Y), in an asymptomatic woman with whose child was considered to develop high onset of OTC deficiency.</text>
					<arg n="0">whose child</arg>
					<arg n="1">high onset of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="22">
					<text>The C-T transition to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic woman carrying whose son was considered to develop at the start of the OTC deficit in the neonatal period.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the OTC deficit in the neonatal period</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son was developing acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="23">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son was developing at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son developed at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="24">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son was found to develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son was observed to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="25">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son was observed to develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son was predicted to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="26">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son was predicted to develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son had developed at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="27">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son was shown to develop high neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">high neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>A C-T transition in codon 214 creating a new RsaI reconnaissance site in exon 6 and replacing tyrosine with histidine (H214Y) was identified in an asymptomatic woman carrying whose son would develop acute neonatal start of OTC deficiency.</text>
					<arg n="0">whose son</arg>
					<arg n="1">acute neonatal start of OTC deficiency</arg>
				</example>
				<example src="EGRAM" no="28">
					<text>The transition C-T to codon 214, which creates a new SRSI recognition site in exon 6 and replaces tyrosine with histidine (H214Y), was identified in an asymptomatic female carrier whose son would develop at the start of the neonatal OTC deficit.</text>
					<arg n="0">whose son</arg>
					<arg n="1">at the start of the neonatal OTC deficit</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>Although Pin1 -/-myth is able to develop usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="29">
					<text>Although Pin1 -/- myce is able to develop usually (Fujimori et al., 1999), we have found that they show a range of proliferative abnormalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>Although Pin1 -/-mouse is considered to develop normally (Fujimori et al., 1999), it has not been found that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="30">
					<text>Although Pin1 -/-mouse is considered to develop usually (Fujimori et al., 1999), it has not been found to have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>Although Pin1 -/-mouses is considered to have developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="31">
					<text>Although Pin1 -/-mouse is considered to have developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>Although Pin1 -/-mouse develops usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="32">
					<text>Although Pin1 -/- myce is found to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>Although Pin1 -/-myce developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="33">
					<text>Although Pin1 -/- myce is found to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>Although Pin1 -/-mouse is expected to develop normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="34">
					<text>Although Pin1 -/-mouse is expected to develop usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>Although Pin1 -/-mouse is expected to have developed normally (Fujimori et al., 1999), it has not been found that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="35">
					<text>Although Pin1 -/-mouse is expected to have developed usually (Fujimori et al., 1999), they have not been found to have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>Although Pin1 -/-myth is able to develop usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="36">
					<text>Although Pin1 -/- myce is able to develop usually (Fujimori et al., 1999), we have found that they show a range of proliferative abnormalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>Although it has been previously thought that Pin1 -/-myce develops usually (Fujimori et al., 1999), we found that they present a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="37">
					<text>Although it was previously believed that Pin1 -/- myce develops usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>Although it is considered that Pin1 -/-mouse developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="38">
					<text>Although Pin1 -/-mouse is considered to have developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>Although Pin1 -/- myce is previously found to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="39">
					<text>Although Pin1 -/-mouse has been previously discovered to develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>Although Pin1 -/-myce has been previously found to developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="40">
					<text>Although Pin1 -/- myce has been previously found to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>Although Pin1 -/-mouse is previously predicted for the development of usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, develop decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="41">
					<text>Although Pin1 -/- myce is predicted to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>Although Pin1 -/-myce is expected to have developed usually (Fujimori et al., 1999), we found that it has a variety of proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="42">
					<text>Although Pin1 -/- myce is predicted to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>Although Pin1 -/-mouse has previously shown to develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including reduced body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="43">
					<text>Although Pin1 -/- myce is previously shown to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>Although Pin1 -/-myth has been previously demonstrated to have developed usually (Fujimori et al., 1999), we found that they present a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="44">
					<text>Although Pin1 -/- myce has previously been shown to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>Although Pin1 -/-mouse develops usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including reduced body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="45">
					<text>Although Pin1 -/-  mice is shown to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0"> mice</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>Although Pin1 -/-mouse proved to have developed usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="46">
					<text>Although Pin1 -/- myce is shown to have developed usually (Fujimori et al., 1999), we have found that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>Although Pin1 -/-mouse can develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including reduced body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="47">
					<text>Although Pin1 -/- myce can develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnormalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>Although Pin1 -/-myce may have developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="48">
					<text>Although Pin1 -/- myce may have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>Although Pin1 -/-myce may have developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="49">
					<text>Although Pin1 -/- myce may have previously developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>Although Pin1 -/-myth may develop M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
				</example>
				<example src="EGRAM" no="50">
					<text>Although Pin1 -/- myce can previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>Although Pin1 -/-mouse can develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including reduced body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="51">
					<text>Although Pin1 -/- myce could develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>Although Pin1 -/-myth may develop M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
				</example>
				<example src="EGRAM" no="52">
					<text>Although Pin1 -/- myce could previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>Although Pin1 -/-mouse is thought to develop usually (Fujimori et al., 1999), it has not been found to have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="53">
					<text>Although it has been thought that Pin1 -/-mouse develops normally (Fujimori et al., 1999), it has not been found that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>Although it has been thought that Pin1 -/-mouses developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="54">
					<text>Although Pin1 -/-mouse has been thought to have developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>Although Pin1 -/-mouse develops usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="55">
					<text>Although Pin1 -/- myce has been found to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>Although Pin1 -/-mouse developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="56">
					<text>Although Pin1 -/- myce has been found to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>Although Pin1 -/-mouse is expected to develop usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="57">
					<text>Although Pin1 -/-mouse has been expected to develop normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>Although Pin1 -/-mouse was expected to developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="58">
					<text>Although Pin1 -/-mouses had been expected to developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>Although Pin1 -/-mouse has shown developing usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="59">
					<text>Although Pin1 -/-mouses has been shown to develop normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>Although Pin1 -/-mouse developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="60">
					<text>Although Pin1 -/- myce has been shown to have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>Although Pin1 -/-myce developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="61">
					<text>Although Pin1 -/- myce has developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>Although it has been previously believed that Pin1 -/- myce develops usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="62">
					<text>Although it has been thought that Pin1 -/-mouse develops normally (Fujimori et al., 1999), it has not been found that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>Although it has been thought that Pin1 -/-mouses developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="63">
					<text>Although Pin1 -/-mouse has been thought to have developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>Although Pin1 -/-mouse has been previously discovered to develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="64">
					<text>Although Pin1 -/- myce has been previously found to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>Although Pin1 -/-mouses has been previously found to developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="65">
					<text>Although Pin1 -/-mouse has been previously discovered to developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>Although Pin1 -/-mouse has been previously predicted for the development of normally (Fujimori et al., 1999), it was not possible to develop that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="66">
					<text>Although Pin1 -/-mouse has been previously predicted for the development of usually (Fujimori et al., 1999), it was not possible to develop that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>Although it has been previously predicted that Pin1 -/-A0 developed usually (Fujimori et al., 1999), we found that they present a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="67">
					<text>Although it was previously predicted that Pin1 -/- A0 had developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>Although Pin1 -/-mouses has been previously demonstrated to have developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="68">
					<text>Although Pin1 -/-mouse has previously been shown to have developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>Although Pin1 -/-myce had developed M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
				</example>
				<example src="EGRAM" no="69">
					<text>Although Pin1 -/- myce has previously developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>Although Pin1 -/-mouse can develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="70">
					<text>Although Pin1 -/- myce can develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnormalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>Although Pin1 -/-myce may have developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="71">
					<text>Although Pin1 -/- myce may have developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>Although Pin1 -/-myce may have developed usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="72">
					<text>Although Pin1 -/- myce may have previously developed usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>Although Pin1 -/-myth may develop M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
				</example>
				<example src="EGRAM" no="73">
					<text>Although Pin1 -/- myce can previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>Although Pin1 -/-mouse can develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="74">
					<text>Although Pin1 -/- myce could develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>Although Pin1 -/-myth may develop M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
				</example>
				<example src="EGRAM" no="75">
					<text>Although Pin1 -/- myce could previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>Although Pin1 -/-myth was able to develop usually (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="76">
					<text>Although Pin1 -/- myce was able to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>Although Pin1 -/- myce was thought to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="77">
					<text>Although Pin1 -/-mouse is thought to develop usually (Fujimori et al., 1999), it has not been found to have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>Although Pin1 -/-mouses had normally developed Fujimori et al., 1999, we did not find a variety of cellular proliferative abnomalies, including reduced body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">Fujimori et al., 1999</arg>
				</example>
				<example src="EGRAM" no="78">
					<text>Although Pin1 -/-mouse had normally developed Fujimori et al., 1999, we do not find a variety of proliferative cellular abnormalities, including reduced body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">Fujimori et al., 1999</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>Although Pin1 -/-mouse is expected to develop usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="79">
					<text>Although Pin1 -/-mouse has been expected to develop normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>Although Pin1 -/-mouse has been able to develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="80">
					<text>Although Pin1 -/- myce was previously able to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>Although it has been thought that Pin1 -/-mouse develops normally (Fujimori et al., 1999), it has not been found that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="81">
					<text>Although Pin1 -/-mouse is thought to develop usually (Fujimori et al., 1999), it has not been found to have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>Although Pin1 -/- myce was previously found to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="82">
					<text>Although Pin1 -/-mouse has been previously discovered to develop usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>Although Pin1 -/-mouse has been previously predicted for the development of usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, develop decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="83">
					<text>Although Pin1 -/- myce was previously predicted to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>Although Pin1 -/-myth has been previously demonstrated to develop usually (Fujimori et al., 1999), we found that they present a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myth</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="84">
					<text>Although Pin1 -/- myce was previously shown to develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>Although Pin1 -/-mouse has shown developing usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="85">
					<text>Although Pin1 -/-mouses has been shown to develop normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>Although Pin1 -/-mouse develops usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="86">
					<text>Although Pin1 -/- myce will develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>Although Pin1 -/-mouses developed normally (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="87">
					<text>Although Pin1 -/-mouse developed usually (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>Although Pin1 -/-mouses had developed normally previously (Fujimori et al., 1999), it was not possible to discover that they have a variety of cellular proliferative abnomalies, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">mouses</arg>
					<arg n="M-MAN">normally</arg>
				</example>
				<example src="EGRAM" no="88">
					<text>Although Pin1 -/-mouse had developed usually earlier (Fujimori et al., 1999), it was not possible to discover that they have a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>Although Pin1 -/-myce develops M-MAN previously (usually) (Fujimori et al., 1999), we found that they have a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
				</example>
				<example src="EGRAM" no="89">
					<text>Although Pin1 -/- myce will previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>Although Pin1 -/-mouse develops usually (Fujimori et al., 1999), we do not find a variety of proliferative cellular abnormalities, including decreased body size, retinal degenation, and neurological abnormalities.</text>
					<arg n="0">mouse</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="90">
					<text>Although Pin1 -/- myce would develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>Although Pin1 -/-myce has developed M-MAN previously (usually) (Fujimori et al., 1999), we found that they present a variety of proliferative abnormalities, including decreased body size, retinal degenation and neurological abnormalities.</text>
					<arg n="0">myce</arg>
				</example>
				<example src="EGRAM" no="91">
					<text>Although Pin1 -/- myce would previously develop usually (Fujimori et al., 1999), we have discovered that they show a range of proliferative abnomalities, including decreased body size, retinal degenration, and neurological abnormalities.</text>
					<arg n="0">myce</arg>
					<arg n="M-MAN">usually</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>A0 has been planted from September to late October, and has been observed to develop in the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="92">
					<text>A0 was planted from September to the end of October, and the evolution in roseta phase was observed and continues to develop until the end of November.</text>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>A0 has been developed from September to late October, and has become the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="93">
					<text>A0 was developed from September to the end of October, and became the roseta phase and continues to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>The A0 is planted from September to late October, and can be developed to the rose stage and continues to grow until late November.</text>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="94">
					<text>A0 is planted from September to the end of October and may be developed for rose phase and continues to grow until the end of November.</text>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>A0 is planted from September to late October, and can be developed in the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="95">
					<text>A0 is planted from September to the end of October and may be developed in roseta phase and continue to grow until the end of November.</text>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>The A0 is planted from September to late October, and develops in the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="96">
					<text>A0 is planted from September to the end of October, and develops in the roseta phase and continues to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>The A0 is planted from September to late October, and has the ability to develop in the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="97">
					<text>A0 is planted from September to the end of October, and has the ability to develop in the roseta phase and continues to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>The A0 is planted from September to late October, and is capable of developing to the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="98">
					<text>A0 is planted from September to the end of October, being able to develop the roseta phase and continues to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>The A0 is planted from September to late October, and is thought to develop in the rosette stage and continues to grow until late November.</text>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="99">
					<text>A0 is planted from September to the end of October, and it is thought to develop in the roseta phase and continues to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>The A0 is planted from September to late October, and is predicted to become the rose stage and develop to grow until late November.</text>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="100">
					<text>A0 is planted from September to the end of October, and it is predicted to become the pink phase and develop to grow until the end of November.</text>
					<arg n="2">the pink phase</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>The A0 is planted from September to late October, and can be developed to the rose stage and continues to grow until late November.</text>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="101">
					<text>A0 is planted from September to the end of October and may be developed for rose phase and continues to grow until the end of November.</text>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>I is planted from September to the end of October and can naturally develop in phase roseta and continue to grow until the end of November.</text>
					<arg n="0">I</arg>
					<arg n="2">roseta</arg>
				</example>
				<example src="EGRAM" no="102">
					<text>A0 is planted from September to the end of October and may develop in the roseta phase and continue to grow until the end of November.</text>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>I is planted from September to the end of October, and it will be shown to develop in the roseta phase and remain growing until the end of November.</text>
					<arg n="0">I</arg>
					<arg n="2">the roseta phase</arg>
				</example>
				<example src="EGRAM" no="103">
					<text>A0 is planted from September to the end of October, and it will be shown to develop in rose phase and continue to grow until the end of November.</text>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>A0 will be planted from September to October, becoming rose phase and will develop to grow until the end of November.</text>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="104">
					<text>The A0 will be planted from September to the end of October, and will become the the rose stage and will develop to grow until the end of November.</text>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>A0 will be planted from September to October, obviously becoming rose phase and will develop to grow by the end of November.</text>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="105">
					<text>The A0 will be planted from September to the end of October, and will obviously become the rose stage and will develop to grow until the end of November.</text>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>stem sown in October is able to develop in roseta phase grows at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="106">
					<text>spinal planted in October which is able to develop in roseta phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>Spinach planted in October can develop in the rose stage and grow until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="107">
					<text>spinal planted in October may develop in rose phase and grow until the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>spinal planted in October may have been developed in rose phase and grown by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="108">
					<text>The sown in October may have been developed in the A2 phase (roseta) and grew by the end of November.</text>
					<arg n="1">sown in October</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>sown in October can be developed in the A2 phase (roseta) and increased by the end of November.</text>
					<arg n="1">sown in October</arg>
				</example>
				<example src="EGRAM" no="109">
					<text>spinal planted in October may develop in rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>stem sown in October developed in roseta phase and grew at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="110">
					<text>spinal planted in October developed rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>spinal planted in October developing in rose phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="111">
					<text>stem sown in October that developing to roseta phase grows at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>The sown of the October had the capability to develop in the A2 phase (roseta) and grew in late November.</text>
					<arg n="1">sown of the October</arg>
				</example>
				<example src="EGRAM" no="112">
					<text>spinal planted in October had the ability to develop in rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>spinal planted in October was converted to rose phase and may developing by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="113">
					<text>sown in October is under development for the pink phase and can developing by the end of November.</text>
					<arg n="1">sown in October</arg>
					<arg n="2">pink phase</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>spinal planted in October developed rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="114">
					<text>The Spinach planted in October has become the rose stage and has developed until the end of November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>The sown in October has the ability to develop in the the rose phase and grow in late November.</text>
					<arg n="1">sown in October</arg>
					<arg n="2">the rose phase</arg>
				</example>
				<example src="EGRAM" no="115">
					<text>spinal planted in October has the ability to develop in rose phase and grow by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>stem sown in October is able to develop in the rosette phase and grow in late November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">the rosette phase</arg>
				</example>
				<example src="EGRAM" no="116">
					<text>spinal planted in October is able to develop in rose phase and grow by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>stem sown in October develops in roseta phase and grows at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="117">
					<text>It is believed that october seed spinel will develop roseta phase and grows by the end of November.</text>
					<arg n="1">october seed spinel</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="118">
					<text>stem sown in October is under development for roseta phase and will developing at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="118">
					<text>The Spinach planted in October is developing the rose stage and will grow until the end of November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="119">
					<text>spinal planted in October developed in roseta phase and grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="119">
					<text>Spinach planted in October is found to develop in the rosette stage and grow until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="120">
					<text>Spinach planted in October is predicted to become the rose stage and develop until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="120">
					<text>stem sown in October is develop for development for roseta phase and growth at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>The sown in October is develop in the the phase of the rosette and grows in late November.</text>
					<arg n="1">sown in October</arg>
					<arg n="2">the phase of the rosette</arg>
				</example>
				<example src="EGRAM" no="121">
					<text>Spinach planted in October is shown to be develop to the rose stage and grows until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="122">
					<text>stem sown in October may develop in roseta phase and grow by the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="122">
					<text>spinal planted in October may develop in rose phase and grow until the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="123">
					<text>stem sown in October may have been developed in roseta phase and grow at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="123">
					<text>The sown in October may have been developed in the A2 phase (roseta) and grew by the end of November.</text>
					<arg n="1">sown in October</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>stem sown in October may develop in roseta phase and increased at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="124">
					<text>sown in October can be developed in the A2 phase (roseta) and increased by the end of November.</text>
					<arg n="1">sown in October</arg>
				</example>
				<example src="EGRAM" no="125">
					<text>spinal planted in October which may develop in rose phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="125">
					<text>The sown of the October that can be developed in phase roseta grows in late November.</text>
					<arg n="1">sown of the October</arg>
					<arg n="2">roseta</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>spinal planted in October develops rose phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="126">
					<text>stem sown in October that develops in roseta phase grows at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>The Spinach planted in October that is able to develop in the rosette stage grows until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="127">
					<text>spinal planted in October which is able to develop in roseta phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>October stem was able to develop in roseta phase and grew at the end of November.</text>
					<arg n="1">October stem</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="128">
					<text>spinal planted in October was able to develop in rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>stem sown in October was developed in roseta phase and grew at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="129">
					<text>It is believed that spinal planted in October has develop rose phase and grown by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>Spinach planted in October was found to have develop the rose stage and grew until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="130">
					<text>spinal planted in October was to rose phase and develop up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>spinal planted in October was expected to develop rose phase and grown towards the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="131">
					<text>It was predicted that the sown of the October would develop in the roseta phase and grew in late November.</text>
					<arg n="1">sown of the October</arg>
					<arg n="2">roseta</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>Spinach planted in October was shown to have develop the rose stage and grew until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="132">
					<text>spinal planted in October was develop to be rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>spinal planted in October which may develop in rose phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="133">
					<text>The sown of the October that can be developed in phase roseta grows in late November.</text>
					<arg n="1">sown of the October</arg>
					<arg n="2">roseta</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>spinal planted in October develops rose phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="134">
					<text>stem sown in October that develops in roseta phase grows at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>The Spinach planted in October that is able to develop in the rosette stage grows until late November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rosette stage</arg>
				</example>
				<example src="EGRAM" no="135">
					<text>spinal planted in October which is able to develop in roseta phase grows by the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>Spinach planted in October will become the rose stage and will develop until the end of November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="136">
					<text>sown of the October will be developed in the A2 phase and will grow in late November.</text>
					<arg n="1">sown of the October</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>The Spinach planted in October will have developed the rose stage and will grow until the end of November.</text>
					<arg n="1">Spinach planted in October</arg>
					<arg n="2">the rose stage</arg>
				</example>
				<example src="EGRAM" no="137">
					<text>sown of the October will be developed in the A2 phase and will grow in late November.</text>
					<arg n="1">sown of the October</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>stem sown in October developed in roseta phase and grew at the end of November.</text>
					<arg n="1">stem sown in October</arg>
					<arg n="2">roseta phase</arg>
				</example>
				<example src="EGRAM" no="138">
					<text>spinal planted in October develop rose phase and grew up to the end of November.</text>
					<arg n="1">spinal planted in October</arg>
					<arg n="2">rose phase</arg>
				</example>
				<example src="EGRAM" no="139">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes is able to develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="139">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens is able to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us is ready to develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="140">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens is ready to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes may develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="141">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens may develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes may have developed a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="142">
					<text>To isolate cDNA DNA clones that dominantly inhibit the binding activity of Oct-2 DNA, chosen as a representative factor, ens may have developed a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>To isolate cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, A0 opts to develop a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="143">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, A0 chooses to develop a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>To isolate cDNA DNA clones that predominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, ens chose to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="144">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us chose to develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us could develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="145">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens could develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>To develop cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, we decided to develop a new screening system.</text>
					<arg n="0">we decided to develop A1 (a new screening system)</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="146">
					<text>To develop cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, we decided to develop a new screening system.</text>
					<arg n="0">we decided to develop A1 (a new screening system)</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>To isolate cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, A0 decided to develop a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="147">
					<text>To isolate DNA clones cDNA that predominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, A0 decided to develop a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>To isolate cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, we develop a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="148">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, we developed a new screening system.</text>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>To isolate cDNA DNA clones that predominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, ens developed a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="149">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us developed a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes had the ability to develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="150">
					<text>To isolate cDNA DNA clones that predominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, ens had the ability to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes was able to develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="151">
					<text>To isolate cDNA DNA clones that dominantly inhibit the binding activity of Oct-2 DNA, chosen as a representative factor, ens was able to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us is ready to develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="152">
					<text>To isolate cDNA DNA clones that dominantly inhibit the binding activity of Oct-2 DNA, chosen as a representative factor, ens has been prepared to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>To isolate cDNA DNA clones that dominantly inhibit the binding activity of Oct-2 DNA, chosen as a representative factor, ens has chosen to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="153">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, we we chose to develop a new screening system.</text>
					<arg n="0">we</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="154">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us decided to develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="154">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens decided to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="155">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, ens developed a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="155">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us developed a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes has the ability to develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="156">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens has the ability to develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes may develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="157">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens may develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes may have developed a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="158">
					<text>To isolate cDNA DNA clones that dominantly inhibit the binding activity of Oct-2 DNA, chosen as a representative factor, ens may have developed a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes may develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="159">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens could develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>To isolate cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, we we are able to develop a new screening system.</text>
					<arg n="0">we</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="160">
					<text>To isolate cDNA DNA clones that predominantly inhibit the DNA binding activity Oct-2, chosen as a representative factor, us us are able to develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>To isolate cDNA DNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as representative factor, we A0 (we others) will be ready to develop a new screening system.</text>
					<arg n="0">we</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="161">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, we we we will be prepared to develop a new screening system.</text>
					<arg n="0">we</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes will develop a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="162">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens will develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, nodes will developed a new screening system.</text>
					<arg n="0">nodes</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="163">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens will developed a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>To isolate cDNA clones that dominantly inhibit Oct-2 DNA binding activity, chosen as a representative factor, us would develop a new screening system.</text>
					<arg n="0">us</arg>
					<arg n="1">a new screening system</arg>
				</example>
				<example src="EGRAM" no="164">
					<text>To isolate cDNA DNA clones that dominantly inhibit the DNA binding activity of Oct-2, chosen as a representative factor, ens would develop a new screening system.</text>
					<arg n="0">ens</arg>
					<arg n="1">a new screening system</arg>
				</example>
			</roleset>
        </predicate>
    </framesest>
</PASBIO>